Novartis Prevails in Antitrust Suits Over Leukemia Drug By Sam | August 24, 2018 A federal appeals court affirmed last week that Novartis did not engage in antitrust violations to protect a patent on its leukemia drug Gleevec (imatinib). Source: Drug Industry Daily Posted in Drug Industry Daily